Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...
Bajaj Healthcare has received approval from India's Drug Controller General to manufacture Pimavanserin, a drug for Parkinson's-related hallucinations and delusions. Pimavanserin, already popular in ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
Brain implants that could help repair the pathways damaged by Parkinson’s disease are being developed by University of ...
Stockhead on MSN17h
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorderAlterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback